Broadening collaboration between SOTIO and Chinese hospitals

Broadening collaboration between SOTIO and Chinese hospitals

During the first day of the 2nd Czech China Health Forum (18th June 2014, Tianjin), Czech and Chinese counterparts signed important memorandums that deepened their collaboration. Three of the MoUs were signed by Mr. Ladislav Bartoníček, CEO of Czech R&D company SOTIO, and three important Chinese university hospitals.

SOTIO is a biotechnology company developing a new Active Cellular Immunotherapy (“ACI”) based on activated dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO continues to develop new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies.